DiaMedica Therapeutics Inc (NAS:DMAC)
$ 2.825 -0.215 (-7.07%) Market Cap: 107.25 Mil Enterprise Value: 69.27 Mil PE Ratio: 0 PB Ratio: 2.32 GF Score: 39/100

DiaMedica Therapeutics Inc To Discuss its ReMEDy2 Update Transcript

Oct 27, 2022 / 12:00PM GMT
Release Date Price: $1.2 (-15.49%)
Operator

Good day, and welcome to DiaMedica Therapeutics ReMEDy2 Update Conference Call. (Operator Instructions) And finally, I would like to advise all participants this call is being recorded. Thank you.

I'd now like to hand over to Rick Pauls to begin the conference. Rick, over to you.

Dietrich John Pauls
DiaMedica Therapeutics Inc. - President, CEO & Director

Good morning. Before we proceed with remarks, please note that we will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements.

More information, including factors that could cause actual results to differ from projected results, appears in the section entitled Cautionary Statement Note regarding forward-looking statements in the company's press release issued yesterday, and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. DiaMedica's SEC filings are available

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot